Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Subscribe To Our Newsletter & Stay Updated
